An Investigational Scan (Deuterium Metabolic Imaging) For Predicting Treatment Effect in Patients with Glioblastoma
This clinical trial studies how well an investigational scan called deuterium metabolic imaging (DMI) works in predicting treatment effects of a drug called BPM31510 in patients with glioblastoma. Investigators believe finding drugs that reverse the abnormal cancer metabolism would be effective in slowing cancer growth with minimal side effects on normal cells. However, there is currently no good way to detect this abnormal cancer metabolism in patients. DMI involves a deuterated-glucose drink solution and magnetic resonance imaging (MRI)/magnetic resonance spectroscopy (MRS) technology for the imaging of metabolism. The MRI scanner uses a strong magnet and a radiofrequency magnetic field to make images of the inside of the body. MRS is similar to MRI and uses the MRI scanner with other imaging software and radiofrequency coils to measure the chemical composition of tissues. Deuterated-glucose is a form of glucose (sugar) where some of its hydrogen atoms are replaced with a heavier version of the hydrogen, called deuterium. The deuterium “tags” the glucose, making it easier to track glucose in scans. DMI may be an effective way to detect abnormal cancer metabolism, which could help investigators study new ways to treat cancer.